文献速递血脂与心血管预防

吸入长效β2激动剂/皮质激素对COPD高心血管风险患者的心血管结局影响

Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk.
PubMed 文献 · Heart · 2017-04-17

SUMMIT为多中心随机双盲安慰剂对照事件驱动试验,纳入16485例中度COPD且伴心血管病或高风险患者。与安慰剂相比,每日吸入维兰特罗25μg、氟替卡松糠酸酯100μg或二者联合均未降低复合心血管事件(HR分别为0.99、0.90、0.93),安全性良好。

要点

  • 在中度COPD且心血管风险高的患者中,吸入维兰特罗、氟替卡松糠酸酯或联合治疗未降低复合心血管事件。
  • 各治疗组复合心血管终点HR的95%CI均跨1,未达统计学显著。
  • 心悸和心律失常等不良事件在各治疗组间无差异。

核心结论

  • 在中度气流受限且心血管风险高的COPD患者中,吸入维兰特罗、氟替卡松糠酸酯或二者联合安全性良好,且不影响心血管结局。

研究设计与样本

  • SUMMIT为多中心、随机、双盲、安慰剂对照、事件驱动试验,纳入16485例中度COPD且患心血管病或处于高风险的患者。
  • 患者随机分入每日吸入安慰剂组(n=4111)、维兰特罗25μg组(n=4118)、氟替卡松糠酸酯100μg组(n=4135)和联合治疗组(n=4121)。
  • 预设次要终点为至首次治疗期间复合心血管事件时间,采用Cox回归分析,并评估临床医生报告的心血管不良事件。

主要发现

  • 受试者以中年男性为主(平均65岁,SD 8;男性75%),66%有明确心血管病。
  • 复合心血管终点共发生688例,首次事件为猝死35%、急性冠脉综合征37%、卒中或短暂性脑缺血发作23%。
  • 与安慰剂相比,维兰特罗组HR 0.99(95%CI 0.80至1.22),氟替卡松糠酸酯组HR 0.90(95%CI 0.72至1.11),联合治疗组HR 0.93(95%CI 0.75至1.14),均未达统计学显著。
  • 各亚组结局相似,包括心悸和心律失常在内的不良事件在各治疗组间无差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Cardiovascular disease (CVD) and chronic obstructive pulmonary disease (COPD) often coexist. We assessed the effect of inhaled COPD treatments on CVD outcomes and safety in patients with COPD and at heightened CVD risk. METHODS: The SUMMIT (Study to Understand Mortality and MorbidITy) was a multicentre, randomised, double-blind, placebo-controlled, event-driven trial in 16 485 patients with moderate COPD who had or were at high risk of CVD. Here, we assessed the prespecified secondary endpoint of time to first on-treatment composite CVD event (CVD death, myocardial infarction, stroke, unstable angina or transient ischaemic attack (TIA)) by Cox regression and by clinician-reported CVD adverse events across the four groups: once-daily inhaled placebo (n=4111), long-acting beta2-agonist (vilanterol (VI) 25 µg; n=4118), corticosteroid (fluticasone furoate (FF) 100 µg; n=4135) and combination therapy (FF/VI; n=4121). RESULTS: Participants were predominantly middle-aged (mean 65 (SD 8) years) men (75%) with overt CVD (66%). The composite CVD endpoint occurred in 688 patients (first event: sudden death (35%), acute coronary syndrome (37%) and stroke or TIA (23%), and was not reduced in any treatment group versus placebo: VI (HR 0.99, 95% CI 0.80 to 1.22), FF (HR 0.90, 95% CI 0.72 to 1.11) and their combination (HR 0.93, 95% CI 0.75 to 1.14). Outcomes were similar among all subgroups. Adverse events, including palpitations and arrhythmias, did not differ by treatment. CONCLUSIONS: In patients with COPD with moderate airflow limitation and heightened CVD risk, treatment with inhaled VI, FF or their combination has an excellent safety profile and does not impact CVD outcomes. TRIAL REGISTRATION NUMBER: NCT01313676.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Brook RD, Anderson JA, Calverley PM, et al. Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk. Heart. 2017. PMID: 28416587. doi:10.1136/heartjnl-2016-310897

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。